The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention
- PMID: 17517448
- PMCID: PMC2075474
- DOI: 10.1016/j.neuint.2007.03.012
The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention
Abstract
Extracellular concentrations of the predominant excitatory neurotransmitter, glutamate, and related excitatory amino acids are maintained at relatively low levels to ensure an appropriate signal-to-noise ratio and to prevent excessive activation of glutamate receptors that can result in cell death. The latter phenomenon is known as 'excitotoxicity' and has been associated with a wide range of acute and chronic neurodegenerative disorders, as well as disorders that result in the loss of non-neural cells such as oligodendroglia in multiple sclerosis. Unfortunately clinical trials with glutamate receptor antagonists that would logically seem to prevent the effects of excessive receptor activation have been associated with untoward side effects or little clinical benefit. In the mammalian CNS, the extracellular concentrations of glutamate are controlled by two types of transporters; these include a family of Na(+)-dependent transporters and a cystine-glutamate exchange process, referred to as system X(c)(-). In this review, we will focus primarily on the Na(+)-dependent transporters. A brief introduction to glutamate as a neurotransmitter will be followed by an overview of the properties of these transporters, including a summary of the presumed physiologic mechanisms that regulate these transporters. Many studies have provided compelling evidence that impairing the function of these transporters can increase the sensitivity of tissue to deleterious effects of aberrant activation of glutamate receptors. Over the last decade, it has become clear that many neurodegenerative disorders are associated with a change in localization and/or expression of some of the subtypes of these transporters. This would suggest that therapies directed toward enhancing transporter expression might be beneficial. However, there is also evidence that glutamate transporters might increase the susceptibility of tissue to the consequences of insults that result in a collapse of the electrochemical gradients required for normal function such as stroke. In spite of the potential adverse effects of upregulation of glutamate transporters, there is recent evidence that upregulation of one of the glutamate transporters, GLT-1 (also called EAAT2), with beta-lactam antibiotics attenuates the damage observed in models of both acute and chronic neurodegenerative disorders. While it seems somewhat unlikely that antibiotics specifically target GLT-1 expression, these studies identify a potential strategy to limit excitotoxicity. If successful, this type of approach could have widespread utility given the large number of neurodegenerative diseases associated with decreases in transporter expression and excitotoxicity. However, given the massive effort directed at developing glutamate receptor agents during the 1990s and the relatively modest advances to date, one wonders if we will maintain the patience needed to carefully understand the glutamatergic system so that it will be successfully targeted in the future.
Figures
Similar articles
-
Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics.J Cell Physiol. 2011 Oct;226(10):2484-93. doi: 10.1002/jcp.22609. J Cell Physiol. 2011. PMID: 21792905 Free PMC article. Review.
-
Acute regulation of sodium-dependent glutamate transporters: a focus on constitutive and regulated trafficking.Handb Exp Pharmacol. 2006;(175):251-75. doi: 10.1007/3-540-29784-7_13. Handb Exp Pharmacol. 2006. PMID: 16722240 Review.
-
Cholesterol depletion attenuates tonic release but increases the ambient level of glutamate in rat brain synaptosomes.Neurochem Int. 2010 Feb;56(3):466-78. doi: 10.1016/j.neuint.2009.12.006. Epub 2009 Dec 16. Neurochem Int. 2010. PMID: 20025918
-
The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics.Neuropharmacology. 2019 Dec 15;161:107559. doi: 10.1016/j.neuropharm.2019.03.002. Epub 2019 Mar 6. Neuropharmacology. 2019. PMID: 30851309 Free PMC article. Review.
-
Functions of glutamate transporters in the brain.Neurosci Res. 2000 May;37(1):15-9. doi: 10.1016/s0168-0102(00)00104-8. Neurosci Res. 2000. PMID: 10802340 Review.
Cited by
-
Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders.Curr Neuropharmacol. 2021;19(7):1069-1089. doi: 10.2174/1570159X18666201015161919. Curr Neuropharmacol. 2021. PMID: 33059576 Free PMC article.
-
Functional investigation of SLC1A2 variants associated with epilepsy.Cell Death Dis. 2022 Dec 21;13(12):1063. doi: 10.1038/s41419-022-05457-6. Cell Death Dis. 2022. PMID: 36543780 Free PMC article.
-
Neuroendocrine aging precedes perimenopause and is regulated by DNA methylation.Neurobiol Aging. 2019 Feb;74:213-224. doi: 10.1016/j.neurobiolaging.2018.09.029. Epub 2018 Oct 5. Neurobiol Aging. 2019. PMID: 30497015 Free PMC article.
-
Pathophysiology, Management, and Therapeutics in Subarachnoid Hemorrhage and Delayed Cerebral Ischemia: An Overview.Pathophysiology. 2023 Sep 14;30(3):420-442. doi: 10.3390/pathophysiology30030032. Pathophysiology. 2023. PMID: 37755398 Free PMC article. Review.
-
Ancient dormant virus remnant ERVW-1 drives ferroptosis via degradation of GPX4 and SLC3A2 in schizophrenia.Virol Sin. 2024 Feb;39(1):31-43. doi: 10.1016/j.virs.2023.09.001. Epub 2023 Sep 9. Virol Sin. 2024. PMID: 37690733 Free PMC article.
References
-
- Anderson CM, Bridges RJ, Chamberlin AR, Shimamoto K, Yasuda-Kamatani Y, Swanson RA. Differing effects of substrate and non-substrate transport inhibitors on glutamate uptake reversal. J Neurochem. 2001;79:1207–16. - PubMed
-
- Aoki M, Lin C-LG, Rothstein JD, Geller BA, Hosler BA, Munsat TL, Horbitz HR, Brown RH. Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis. Ann Neurol. 1998;43:645–653. - PubMed
-
- Aoyama K, Suh SW, Hamby AM, Liu J, Chan WY, Chen Y, Swanson RA. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci. 2006;9:119–26. - PubMed
-
- Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry. 2006;63:769–76. - PubMed
-
- Aronica E, Gorter JA, Ljlst-Keizsers H, Rozemuller AJ, Yankaya B, Leenstra S, Troost D. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci. 2003;17:2106–2118. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MH071008/MH/NIMH NIH HHS/United States
- R01 NS036465/NS/NINDS NIH HHS/United States
- R01 NS039011/NS/NINDS NIH HHS/United States
- NS29868/NS/NINDS NIH HHS/United States
- R01 NS036465-10/NS/NINDS NIH HHS/United States
- NS36465/NS/NINDS NIH HHS/United States
- R01 NS039011-07/NS/NINDS NIH HHS/United States
- R01 NS029868/NS/NINDS NIH HHS/United States
- NS39011/NS/NINDS NIH HHS/United States
- R01 NS029868-13/NS/NINDS NIH HHS/United States
- R01 HD060132/HD/NICHD NIH HHS/United States
- F31 MH071008/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical